Related references
Note: Only part of the references are listed.Circulating Platelet-Activating Factor Is Primarily Cleared by Transport, Not Intravascular Hydrolysis by Lipoprotein-Associated Phospholipase A2/PAF Acetylhydrolase
Jinbo Liu et al.
CIRCULATION RESEARCH (2011)
OxLDL stimulates lipoprotein-associated phospholipase A2 expression in THP-1 monocytes via PI3K and p38 MAPK pathways
Wen-Yi Wang et al.
CARDIOVASCULAR RESEARCH (2010)
Lipoprotein-associated phospholipase A(2), C-reactive protein, and coronary artery disease in individuals with type 1 diabetes and macroalbuminuria
Rachel G. Miller et al.
DIABETES & VASCULAR DISEASE RESEARCH (2010)
Biology of Platelet-activating Factor Acetylhydrolase (PAF-AH, Lipoprotein Associated Phospholipase A2)
Diana M. Stafforini
CARDIOVASCULAR DRUGS AND THERAPY (2009)
Phospholipase A2 Biochemistry
John E. Burke et al.
CARDIOVASCULAR DRUGS AND THERAPY (2009)
The evaluation of IL-12 concentration, PAF-AH, and PLA2 activity in patients with type 1 diabetes treated with intensive insulin therapy
Malgorzata Wegner et al.
CLINICAL BIOCHEMISTRY (2009)
Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial - a randomized controlled study
Sang-Ho Jo et al.
AMERICAN HEART JOURNAL (2008)
Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque
Patrick W. Serruys et al.
CIRCULATION (2008)
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent
Emile R. Mohler et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development
Robert L. Wilensky et al.
NATURE MEDICINE (2008)
Oxidized phospholipids reduce ventilator-induced vascular leak and inflammation in vivo
Stephanie Nonas et al.
CRITICAL CARE (2008)
Platelet-Activating Factor (PAF): A Review of its Role in Asthma and Clinical Efficacy of PAF Antagonists in the Disease Therapy
Alicja Kasperska-Zajac et al.
RECENT PATENTS ON INFLAMMATION & ALLERGY DRUG DISCOVERY (2008)
Mouse models for atherosclerosis and pharmaceutical modifiers
Susanne Zadelaar et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects
Margaretha Persson et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death
Heidi T. May et al.
AMERICAN HEART JOURNAL (2006)
Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community
Yariv Gerber et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress
Wolfgang Koenig et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Inflammation, atherosclerosis and cardiovascular disease risk:: PAPP-A, Lp-PLA2 and cystatin C.: New insights or redundant information?
P Píñon et al.
REVISTA ESPANOLA DE CARDIOLOGIA (2006)
Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke
MJ Caslake et al.
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE (2005)
Role of lipoprotein-associated phospholipase A2 in atherosclerosis -: Biology, epidemiology, and possible therapeutic target
A Zalewski et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up
ES Brilakis et al.
EUROPEAN HEART JOURNAL (2005)
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study
CM Ballantyne et al.
CIRCULATION (2004)
Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial
S Opal et al.
CRITICAL CARE MEDICINE (2004)
Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population -: Results from the 14-year follow-up of a large cohort from southern Germany
W Koenig et al.
CIRCULATION (2004)
Oxidized phospholipids as modulators of inflammation in atherosclerosis
N Leitinger
CURRENT OPINION IN LIPIDOLOGY (2003)
Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase
AD Tselepis et al.
ATHEROSCLEROSIS SUPPLEMENTS (2002)
Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime
D Steinberg
NATURE MEDICINE (2002)
Lysophosphatidylcholine stimulates monocyte chemoattractant protein-1 gene expression in rat aortic smooth muscle cells
JX Rong et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2002)
Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease.
CJ Packard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Effect of recombinant human platelet-activating factor-acetylhydrolase on allergen-induced asthmatic responses
NR Henig et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2000)
Share Paper
